A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI) (EF099)
This study has been completed.
Sponsor:
Eurofarma Laboratorios S.A.
Information provided by (Responsible Party):
Eurofarma Laboratorios S.A.
ClinicalTrials.gov Identifier:
NCT01145339
First received: June 15, 2010
Last updated: June 22, 2012
Last verified: October 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study primary objective is to compare the clinical efficacy of two formulations in the supportive treatment of lactose intolerance.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypolactasia |
Drug: Lactase |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
| Official Title: | A Phase III, Non-Inferiority, Randomized, Double-Blind, Parallel-Group, Multicentre, Single-Dose, Comparative Clinical Study of Lactase Eurofarma (Test Drug) and Lactaid® (Comparative Drug), Assessing the Efficacy and Safety in the Treatment of Patients With Lactose Intolerance (Hypolactasia) |
Resource links provided by NLM:
Genetics Home Reference related topics:
lactose intolerance
MedlinePlus related topics:
Lactose Intolerance
U.S. FDA Resources
Further study details as provided by Eurofarma Laboratorios S.A.:
Primary Outcome Measures:
- Hydrogen value in the air expired [ Time Frame: 03 times ] [ Designated as safety issue: No ]Hydrogen value in the expired air for 3h after the patient exposure to the standardized Lactose 25g dose with interventional exogenous Lactase (comparative and test drugs).
| Enrollment: | 140 |
| Study Start Date: | July 2011 |
| Study Completion Date: | March 2012 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Lactase EUF
1 chewable tablet of the test drug 30 minutes before the standard lactose dose (25 g).
|
Drug: Lactase
1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
|
|
Active Comparator: Lactase Ref
1 chewable tablet of the comparative drug 30 minutes before the standard lactose dose (25 g).
|
Drug: Lactase
1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
|
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- The patient should be a male or female, aged between 18 and 60 years old;
- Have a medical history consistent with lactose intolerance, confirmed by the test of hydrogen in the expired air;
- The female patients should agree to use birth control methods during the study participation;
- To be able to meet the study instructions and all the visits required;
- To give a free consent to participate in the study and sign the informed consent form (ICF).
Exclusion Criteria:
- Smoking;
- Secondary hypolactasia;
- Gastrointestinal inflammatories diseases - present diverticular disease, diabetic gastropathy or neoplasias;
- Colonoscopy or colon cleaning procedure 4 weeks before the start of study
- Latrogenic: unnoticed intake of laxatives in over-the-counter drugs or alternative medicine, intake of cereal bran or probiotics;
- Diagnosis of HIV, immunodepression of any origin, or cancer under treatment.
- Diagnosis of other comorbidity that, at the investigator's discretion, may compromise the study participation (e.g., systemic infection during the study or use of antibiotics in the last 4 weeks, diabetes mellitus, uncontrolled hypertension or renal failure),
- Hypersensitivity or previous laboratory or clinical adverse event related to the use of lactase or any of the components of the formulations used in the study;
- Incapacity to understand and complete the study questionnaires, including the questions that require the use of the Visual Analogue Scale and ICF;
- Pregnancy or lactation;
- Use of alcohol, exceeding 3 doses daily;
- Participation in another clinical study on the last 12 months;
- Patient having some chronic pulmonary disease that, in the investigator's opinion, may harm or interfere with the expired hydrogen test (e.g., cystic fibrosis).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01145339
Locations
| Brazil | |
| Instituto Goiano de Gastroenterologia | |
| Goiania, GO, Brazil | |
| Instituto Alfa de Gastroenterologia | |
| Belo Horizonte, MG, Brazil | |
| Hospital Nossa Senhora das Graças | |
| Curitiba, PR, Brazil | |
| Hospital São Lucas | |
| Porto Alegre, RS, Brazil, 90610-000 | |
| Hospital Mãe de Deus | |
| Porto Alegre, RS, Brazil | |
| Faculdade de Medicina do ABC | |
| Santo André, SP, Brazil | |
| Hospital São Paulo / UNIFESP | |
| São Paulo, SP, Brazil | |
Sponsors and Collaborators
Eurofarma Laboratorios S.A.
Investigators
| Principal Investigator: | Aderson Damião, M.D | Hospital das Clínicas de São Paulo |
| Principal Investigator: | Heda Amarante, M.D | Hospital Nossa Senhora das Graças |
| Principal Investigator: | Marta Machado, M.D | Hospital São Lucas PUCRS |
| Principal Investigator: | Sender Miszputen, M.D | Hospital São Paulo / UNIFESP |
| Principal Investigator: | Wilson Catapani, M.D | Faculdade de Medicina do ABC |
| Principal Investigator: | Mauro Bafutto, M.D | Instituto Goiano de Gastroenterologia |
| Principal Investigator: | Carlos Francesconi, M.D | Hospital Mãe de Deus |
| Principal Investigator: | Maria do Carmo Passos, M.D | Instituto Alfa de Gastroenterologia de BH |
More Information
No publications provided
| Responsible Party: | Eurofarma Laboratorios S.A. |
| ClinicalTrials.gov Identifier: | NCT01145339 History of Changes |
| Other Study ID Numbers: | EF099 |
| Study First Received: | June 15, 2010 |
| Last Updated: | June 22, 2012 |
| Health Authority: | Brazil: Ethics Committee Brazil: National Health Surveillance Agency |
ClinicalTrials.gov processed this record on May 21, 2013